机构：[1]Department of Thoracic Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, China.[2]Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.[3]Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China.[4]Department of Pathology, Taizhou Cancer Hospital, Taizhou, Zhejiang, China.浙江省肿瘤医院[5]Department of Oncology, The Affiliated Jiangyin Hospital of Nantong University, Jiangyin, Jiangsu, China.[6]Department of Thoracic Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.四川省人民医院[7]Department of Thoracic Surgery, Sichuan Translational Medicine Research Hospital, Chinese Academy of Sciences, Chengdu, China.四川省人民医院
Project of Jiangsu Provincial
Health Commission (H2019103) and the Major Scientific
Research Project of Wuxi Commission of Health (Z202201)
to Dong Shen, as well as the Natural Science Foundation
of Fujian Province (2021J01364) to Tianxing Guo.
第一作者机构：[1]Department of Thoracic Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, China.
共同第一作者：
通讯作者：
通讯机构：[5]Department of Oncology, The Affiliated Jiangyin Hospital of Nantong University, Jiangyin, Jiangsu, China.[6]Department of Thoracic Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.[7]Department of Thoracic Surgery, Sichuan Translational Medicine Research Hospital, Chinese Academy of Sciences, Chengdu, China.[*1]Department of Oncology, The Affiliated Jiangyin Hospital of Nantong University, Jiangyin 214400, Jiangsu, China.[*2]Department of Thoracic Surgery, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Sichuan Translational Medicine Research Hospital, Chinese Academy of Sciences, Chengdu 610072, China.
推荐引用方式(GB/T 7714)：
Guo Tianxing,Wang Zhaofeng,Wang Song,et al.Predictive value of DOT1L mutations for clinical outcomes in non-small-cell lung cancer patients receiving immune checkpoint inhibitor therapy[J].CLINICAL AND TRANSLATIONAL MEDICINE.2023,13(10):doi:10.1002/ctm2.1430.
APA：
Guo Tianxing,Wang Zhaofeng,Wang Song,Zhang Yaru,Pang Jiaohui...&Li Gang.(2023).Predictive value of DOT1L mutations for clinical outcomes in non-small-cell lung cancer patients receiving immune checkpoint inhibitor therapy.CLINICAL AND TRANSLATIONAL MEDICINE,13,(10)
MLA：
Guo Tianxing,et al."Predictive value of DOT1L mutations for clinical outcomes in non-small-cell lung cancer patients receiving immune checkpoint inhibitor therapy".CLINICAL AND TRANSLATIONAL MEDICINE 13..10(2023)
